Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age: 18 - 80~* bioptical confirmed adenocarcinoma of the rectum in T3NxM0 status. The tumor has to be basically surgically complete resectable (-\>R0).~* no former chemotherapy, radiotherapy of pelvis or abdomen and/or tumor resection of rectum carcinoma~* WHO performance status 0-2~* adequate bone marrow reserve (granulocytes \>= 3.000/µl, absolute neutrophil \>= 0 1,5 x 10 9/l thrombocytes: \>= 100.000/µl, haemoglobin \>= 10g/dl)~* adequate hepatic function (Bilirubin: \<= 1.5 x ULN, GOT und GPT \<= 2.5 x ULN)~* adequate renal function (creatinin: \<= 1.25 mg/dl, creatinin-clearance: \> 50 ml/min (Cockcroft and Gault formula)), proteinuria: dipstick \< 2+. In case of dipstick \> 2+ protein has to be measured in 24h urine and does not exceed more than 1g/24h)~* ability of intake of pills~* women of childbearing potential: exclusion of pregnancy (negative urin or serum pregnancy test)~* willingness of women of childbearing potential and accordingly of potent men to use approved contraceptives (e.g. birth-control pill, loop, condom) during and at least 3 month after conclusion of the study~* life expectancy of at least 3 month~* INR and aPTT \< 1.5 ULN~* signed Informed Consent before recruitment~Exclusion Criteria:~* failure of one inclusion criteria~* former radiotherapy of pelvis or abdomen~* former chemotherapy~* any other kind of malign tumor in the last 5 years~* any other kind of tumour in the last 5 years with exception of basal cell carcinoma of skin and cervix carcinoma in situ~* general contraindication or known hypersensitivity against Bevacizumab and/or Capecitabine~* non malign disease, if there is a contraindication with radiotherapy, or chemotherapy with Bevacizumab and Capecitabine, or a resection of rectum: uncontrolled hypertension (systolic \> 150 mmHG and/or diastolic \>100 mmHG) or clinical significant (e.g. active) cardiovascular disease: CVA (cardiovascular accident)/ cerebral apoplexy (\< 6 months before recruitment), myocardial infarct (\< 6 months before recruitment), instable angina pectoris, CHF with NYHA status II or higher, or treated serious arrhythmia, hepatic disease, significant neurologic or psychiatric disorders~* florid, serious infections at the time of recruitment~* peripheral neuropathy (NCI CTC \>= Grade 1)~* legally limited contractual capability or evidence of neurological or psychiatric disease, if it will constrict the patients compliance in the opinion of the investigator~* evidence of lacking cooperation of the patient~* major intervention within 28 days before recruitment, open wounds~* serious injuries, unhealed wounds or fractures~* patients with spinal compressions or metastases in central nervous system~* evidence of bleeding diathesis or coagulation dysfunction~* actual intake of anticoagulant or thrombolytic agents, Aspirin \> 325 mg/d or within 10 days before study start)~* actual or recent (within 10 days before recruitment) therapeutic therapy with fully-dosed anticoagulants. A prophylactic treatment is permitted.~* previous thromboembolic or hemorrhagic events within the last 6 months before recruitment~* previous abdominal fistulas, GI perforation or intra-abdominal abscess within the last 6 months~* treatment with other study medication within 28 days before recruitment~* patients with malabsorption syndrome or difficulties swallowing~* pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).